Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

NCT03215719 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Oropharyngeal Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

RADIATION: Standard Radiation Treatment
RADIATION: Dose-Deescalated Treatment
DRUG: Cisplatinum

Sponsor

NYU Langone Health